An important role in the development of obstetric hemorrhage, both during pregnancy and in childbirth and the postpartum period, is played by: antenatal fetal death, varicose disease, gestational and chronic pyelonephritis, hypertension, neuroendocrine diseases and, of course, preeclampsia. It performed the analysis of literature data on the use of the drug carbetocin for the treatment of obstetric hemorrhage after cesarean section (CS). A high probability of further increasing the frequency of CS performance was noted, with so far unified approaches to the prevention of postpartum hemorrhage (PPH) have not been developed, the search for the most safe and effective treatment tactics for emergency CS is conducted. In the 90s of the last century, carbetocin, a synthetic analogue of human oxytocin with structural modifications that prolong its half-life in the body, was proposed for use in clinical practice, which increases the duration of the effect of the drug by 4–10 times. Available data to date suggest a higher efficacy of carbetocin for the prevention and treatment of postpartum hemorrhage compared with oxytocin and other drugs and their combinations. Studies to date have shown that the incidence of side effects with carbetocin is not higher than with oxytocin. The drug is no less effective than syntometrin, so it can be an alternative uterotonic agent for the prevention of PPH after spontaneous delivery and operative delivery. However, there is no evidence from evidence-based studies assessing the efficacy and safety of using this drug when performing CS, changes in the hemostasis system in pregnant women using carbetocin are not characterized. The need for further research to clarify the safety profile of the drug carbetocin in the presence of concomitant diseases in the pregnant women is indicated.